Important legal notice
Contact   |   Search on Europa   

Infectious Diseases Graphic element print icon Graphic element
  Homepage
Graphic element General information
  RTD Infectious Diseases Unit
  Developing countries
  EDCTP
   
Graphic element Projects
  About FP6 Funding
  FP6 projects
  About FP5 Funding
  FP5 projects
   
   
Graphic element Addressed Diseases
  HIV/AIDS
- News
  Malaria
  Tuberculosis
   
Graphic element Calls for proposals
  FP7 Calls
   
Graphic element Contact corner
  Unit
  Scientific officers
  Subscribe to our mailing list
   
 
NEAT
HIV/AIDS
Framework programme: 6
Call: 4
Project number: LSHP-CT-2006-037570
EC contribution: € 12,500,000
Duration: 60 Months
Type: NoE
Starting date: 1st February 2007
Graphic element The European AIDS Treatment Network
Keywords: HIV, AIDS, Antiretroviral Therapy, Clinical Research, Europe, Networking, Research and Spreading

Summary:

NEAT’s mission is to strengthen European HIV clinical research capacity by building a clinical and laboratory network in HIV therapeutics. NEAT will catalyse a critical mass of resources and expertise, with the direct involvement of 41 core partners from 16 countries and over 350 affiliated centres of established international reputation. NEAT is committed to designing the roadmap for a durable reshaping of the way clinical research is carried out in Europe so as to achieve a progressive and lasting integration. In doing so, NEAT will pave the way toward the creation of the European Research Area.

The Network will also spread expertise and resources provide training and mobility of scientists at all levels and will foster lasting collaborations across Europe.

Background:

Academic and publicly driven transnational and clinical research in Europe is still fragmented and insufficiently funded, despite some relevant examples of at least partial integration and coordination (e.g. cancer and cardiovascular research). In fact, the majority of preclinical and phase I-III clinical research is carried out by the pharmaceutical industry. In the HIV infection and AIDS area, public investments and coordination varies considerably from country to country, with only a few countries having specific National Programmes providing funding, and/or Central Coordinating Institutions providing technical support to clinical research within the country.

Combination antiretroviral therapy has resulted in a dramatic decrease in mortality and HIV-associated morbidity in industrialised countries. Nevertheless, many serious issues and challenges – namely long term toxicity and HIV drug resistance - are problematic and important in the management of HIV infected individuals, even when treated according to the state-of-the-art. The need for further advances in clinical governance and management of HIV infection remains a high priority, both from a public health and from a medical research perspective.

Aim:

NEAT includes 41 partner institutions from 16 European Countries, with over 350 affiliated centres, caring for the vast majority of persons living with HIV/AIDS in Europe. During the Network development phase, NEAT plans to incorporate all European countries, particularly from the central/eastern region.

Activities will focus on developing new strategies and approaches, from combination antiretroviral therapy to immune-based therapies to treatment of HIV-hepatitis co-infections, promoting networking of transnational research, from proof-of-principle, to phase III - IV clinical trials.

The Network will disseminate expertise and resources, provide training and mobility of scientists at all levels and foster long-term collaborations that will empower European HIV clinical research. A strong educational programme will improve the knowledge of HIV medicine and treatment will be homogenised throughout Europe, avoiding inequalities of care. NEAT will bring together over 350 clinical centres - will improve the harmonisation of medical practices throughout Europe, which will go beyond HIV/AIDS.

Expected results:

  • To strengthen the research capacity throughout Europe by building a network for clinical therapeutic trials in HIV in order to optimise the management of HIV;
  • To define optimal strategies for management of HIV infection and to guide the implementation of optimal interventions;
  • To improve coherence, complementarities and integration and to develop a common research programme in HIV research;
  • To spread excellence through training, mobility and informative programmes (including public events, conferences, website);
  • To bring together the existing but dispersed critical mass of researchers (more than 200 scientists) and expertise in Europe from leading Institutions and Organisations (5 National Agencies, 2 established consortia, 15 leading clinical Institutions and 1 European Patient Association);
  • To integrate leading HIV/AIDS research Institutions and Clinical Centres through a coherent, multidisciplinary and durable research programme;
  • To tackle fragmentation and strengthen excellence by creating a Clinical Trials Platform to improve the efficacy and coherence of ongoing HIV/AIDS clinical research in Europe;
  • To design the roadmap for a durable restructuring and reshaping of the way research is carried out in Europe to achieve a desired level of integration, in the medium/long term;
  • To significantly increase the quality and ambitions of existing research in order to affirm Europe’s leadership in the field;
  • To promote quality and excellence through the establishment of a PhD and post doctoral programme to train young scientists.

Coordinator:

1 - Stefano Vella MD
Istituto Superiore di Sanità [the Italian National Institute of Health]
Viale Regina Elena 299
Rome-00161
Italy
Tel: +39 06 4990 6015 / 49906016
Mobile: +39 348 2650598
Fax: +39 06 4990 2012
E-mail: stefanovella@iss.it
Website: www.iss.it

Partners:


Principal
Scientific
Participants
Official Address Other Information
2Stefano VellaIstituto Superiore di Sanità
Dipartimento del Farmaco
Roma IT-CA
3Jean-Francois DelfraissyAgence Nationale de Reserches sur le SIDA et les Hepatites Virales
Paris FR-CA
4Norbert BrockmeyerCompetence Network HIV/AIDS,
Ruihr-Universitat Bochum
Bochum D-CA
5Abdel BabikerMedical Research Council,
Clinical Trial Unit
LondonUK-CA
6Joep LangeAcademic Medical Centre
National AIDS Therapy Evaluation Centre
Amsterdam NL-CA
7William PowderlyUniversity College Dublin
School of Medicine and Medical Science
Dublin IRE
8Francisco AntunesFacultade de Medicina de Lisboa,
Clinica Universitaria de Doencas Infecciosas
Lisboa PT
9Jose M. GatellHospital Clinic i Provincial de Barcelona
Infectious Diseases & AIDS Unit
Barcelona ES-1
10Bonaventura ClotetFundacio LLuita contra la SIDA,
HIV Unit
Badalona ES-2
11Vicente SorianoHospitalCarlos III
Department of Infectious Diseases
Madrid ES-3
12Jose ArribasHospital La Paz, HIV Unit
Madrid ES-4
13Natan ClumeckSaint Pierre University Hopital
Department of Infectious Diseases
Bruxelles B
14Andrzej HorbanWojewodzki Szpital Zakazny
AIDS Diagnosis and Therapy Centre
Warszawa PL
15Ladislav MachalaAIDS Center Faculty Hospital Bulovka
Prague CZ-1
16Dalibor SedlacekUniversity Hospital Plzen
Plzen CZ-2
17Denes Banhegyi St Laszlo Hospital,
5th Dept of Medicine
Budapest HU
18Anders SonnerborgKarolinska University Hospital
Department of Infectious Diseases
Stockholm SE
19Jens D. LundgrenH:S Hvidovre Hospital,
Copenhagen HIV Programme, Dept 044
Hvidovre DK
20Christine KatlamaHopital Pitie-Salpetriere,
Département des maladies infectieuses
Paris FR-1
21Jean-Michel MolinaHopital Saint-Louis, Centre
Hospitalier Universitaire et de Recherche
Paris FR-2
22Patrick YeniCHU Bichat, Assistance Publique Hopitaux de Paris
Department of Infectious Diseases
Paris FR-3
23Francois RaffiCentre Hospitalier Universitaire de Nantes, Department of Infectious
Diseases, HIV Clinical Research Unit
Nantes FR-4
24Francoise BrunUniversity Paris 7
Denis Diderot, lab of Virology, Bichat
Claude Bernard Hospital
Vezinet Paris FR-5
25Yves LevyCentre Hospitale Universitaire Henri
Mondor, Service d’Immunologie Clinique
Paris FR-6
26Jürgen RockstrohDepartment of Medicine, University of Bonn
Bonn D-1
27Reinhold E. SchmidtAbteilung Klinische Immunologie,
Medizinische Hochschule Hannover
Hannover D-2
28Schlomo StaszewskiHospital of the Johann Wolfgang Goethe University, Dep. of InternalMedicine,
HIV Outpatient and Research Unit
Frankfurt HIV Cohort
Frankfurt am Main D-3
29Andrea AntinoriNational Institute of Infectious Diseases "L. Spallanzani"
Roma IT-1
30Giampiero CarosiUniversità degli Studi di Brescia, Spedali
Civili - Clinica Malattie Infettive e Tropicali
Brescia IT-2
31Giuseppe TambussiFondazione Centro San Raffaele
del Monte Tabor, Infectious Diseases
Milano IT-3
32Massimo AndreoniUniversità degli Studi di Tor Vergata,
Dep. of Pubblic Health/Clinical of InfectiousDiseases,
Faculty of Medicine
Roma IT-4
33Anton PozniakUniversità degli Studi di Milano
UNIMI Mauro MoroniMilano IT-5
St Stephen's AIDS Trust,
Department of HIV
LondonUK-1
34Andrew PhillipsRoyal Free & University College,
Medical School of UCL
LondonUK-2
35Charles BoucherUniversity Medical Center Utrecht,
Department of Virology
Utrecht NL-1
36Remko van LeeuwenInternational Anti-Viral Therapy
Evaluation Centre
Amsterdam NL-2
37Brigitte SchmiedSozialmedizinisches Zentrum
Baumgartner Höhe - Otto-Wagner-Spital
mit Pflegezentrum
Wien AT-2
38Patrick FrancioliSwiss HIV Cohort Study
Lausanne NET-CH
39Carlo GiaquintoPENTA - for the treatment and care of children with HIV (and related diseases) - ONLUS
Padova NET-PED
40Marisa De RosaEuropean AIDS Treatment Group e.
V.EATG Nikos Dedes Dusseldorf
NET-COM CINECA,
Consorzio Universitario
Bologna IT-IT

 
 
top
Graphic element